论文部分内容阅读
目的探讨重组人p53腺病毒注射液治疗晚期卵巢癌的近期疗效。方法 2009年5月至2010年12月间收治的20例晚期卵巢癌患者给予重组人p53腺病毒注射液局部或全身治疗±化疗±热疗治疗,每2个月评价疗效。结果随访12个月,20例晚期卵巢癌中,完全缓解(CR)4例(20.0%),部分缓解(PR)9例(45.0%),稳定(SD)5例(25.0%),进展(PD)2例(10.0%)。18例恶性胸、腹腔积液患者中,CR 5例(27.8%),PR 7例(38.9%),SD 6例(33.3%)。患者总体不良反应轻微,Ⅰ~Ⅱ度自限性发热12例。结论重组人p53腺病毒注射液联合化疗治疗晚期卵巢癌患者疗效好,不良反应可控。
Objective To investigate the short-term curative effect of recombinant human adenovirus p53 in the treatment of advanced ovarian cancer. Methods Twenty patients with advanced ovarian cancer who were treated between May 2009 and December 2010 were given local or systemic chemotherapy with recombinant adenovirus p53 plus chemotherapy plus hyperthermia and evaluated every two months. The results were followed up for 12 months. Among 20 patients with advanced ovarian cancer, complete remission (CR) occurred in 4 cases (20.0%), partial remission (PR) in 9 cases (45.0%), stable PD) in 2 cases (10.0%). In 18 patients with malignant pleural effusion and ascites, 5 (27.8%) were CR, 7 (38.9%) were PR and 6 (33.3%) were SD. Patients with mild overall adverse reactions, Ⅰ ~ Ⅱ degree self-limited fever in 12 cases. Conclusion Recombinant human p53 adenovirus injection combined with chemotherapy for advanced ovarian cancer patients with good efficacy and adverse reactions can be controlled.